American Diabetes Association. Aspirin therapy in diabetes. Diabetes Care 1999; 22 (Suppl 1): S60-S61.

American Diabetes Association. Implications of the United Kingdom Prospective Diabetes Study. Diabetes Care 1999; 22 (Suppl 1):S27-S31.

Centanni M, Marignani M, Gargano L et al. Atrophic body gastritis in patients with autoimmune thyrid disease. Ach Intern Med 1999; 159:1726-30.

Chaturvedi N, Sjolie AK, Stephenson JM et al. Effect of lisinopril on proression of retinophaty in normotensive people with type 1diabetes. Lancet 1998; 351:28-31.

Dayan CM, Daniels GH. Chronic autoimmune thyroiditis. N Engl J Med 1996; 335:99-107.

DeFronzo RA. Pharmacologic Therapy for type 2 diabetes mellitus. Ann Inter Med 1999; 131:281-303.

Eisenbarth GS, Verge CF. Immunoendocrinopathy Syndromes. En Williams Textboook of Endocrinology. JD Wilson, DW Foster, HM Kronenberg, PR Larsen Editores. Editorial WB Saunders Company 1998, 33: 1651-1662.

European Diabetes Policy Group. A Desktop Guide to Type 1 (Insulin-dependent) Diabetes Mellitus. Guidelines for Diabetes Care. International Diabetes Federation European Region 1998.

European Diabetes Policy Group. A Desktop Guide to Type 2 Diabetes Mellitus. Guidelines for Diabetes Care. International Diabetes Federation European Region 1999.

Groop LC, Bottazzo GF, Doniach D. Islet cell antibodies identify latent type 1 diabetes in patients aged 35-75 years at diagnosis. Diabetes 1986; 35: 237-241.

Guidelines Subcommittee 1999. World Health Organization-International Society of Hypertention guidelines for the management of hypertension. J Hipertens 1999; 17:151-183.

Hansson L, Zanchetti A, Carruthers SG et al. Effects of intensive blood pressure lowering and low dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomized trial. Lancet 1998; 351:1755-1762.

Larsen RP, Davies TF, Kovacs WJ. The thyroid gland. En Williams Textboook of Endocrinology. JD Wilson, DW Foster, HM Kronenberg, PR Larsen Editores. Editorial WB Saunders Company 1998, 11: 389-516.

Lawson ML, Gerstein HC, Tsui E, Zinman B. Effect of intensive therapy on early macrovascular disease in young individuals with type 1 diabetes. Diabetes Care 1999; 22 (Suppl 2): B35-B39.

Lebovitz HE. Oral antidiabetic agents. Drugs 1992; 44 (Suppl 3): 21-28.

Lindsay RS, Toft AD. Hypothyroidism. Lancet 1997; 349:413-17.

Lurbe E, Redón J. Preesión arterial y diabetes mellitus tipo 1: ¿qué aporta la medida de la presión arterial ambulatoria?. Med Clin (Barc) 1999; 112:294-96.

Mandel SJ, Brent GA, Larsen RL. Levothyroxine therapy in patients with thyroid disease. Ann Intern Med 1993; 119:492-502.

Mogensen CE. Microalbuminuria, blood pressure and diabetic renal disease: origin and development of ideas. Diabetologia 1999; 42:263-85.

Nathan DM. Inferences and implications. Do results from the diabetes control and complications trials apply in NIDDM? Diabetes Care 1995; 18:251-257.

Ohkubo Y, Kishikawa H, Araki E et al. Intensive insulin therapy prevents the progression of microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-years study. Diabetes Res Clin Pract 1995; 28:103-117.

Parving HH. Renoprotection in diabetes: genetic and non-genetic risk factors and treatment. Diabetologia 1998; 41:745-759.

Perfetti R, Barnett PS, Mathur R, Egan JM. Novel therapeutic strategies for the treatment of type 2 diabetes. Diabetes Metab Rev 1998; 14:207-225.

Poulsen PL, Bek T, Ebbehoj E, Hansen KW, Mogensen CE. 24 h ambulatory blood pressure and retinopathy in normoalbuminuric IDDM patients. Diabetologia 1998; 41:105-110.

Poulsen PL, Ebbehoj E, Hansen KW, Mogensen CE. Characteristics and prognosis of normoalbuminuric type 1 diabetic patients. Diabetes Care 1999; 22(Suppl 2): B72-B75.

Skyler J, Marks J. Imune intervention in type 1 diabetes mellitus. Diabetes Rev 1993; 1:15-42.

Skyler JS. Insulin therapy in type 2 diabetes mellitus. En "Current therapy of diabetes mellitus". DeFronzo RA Ed. St Louis, MO, Mosby, 1998, 108-116.

Skyler JS. Insulin treatment. En " Therapy for diabetes mellitus and related disordes". Lebovitz HE Ed. 3er Ed. Alexandria VA: American Diabetes Association, 1998:186-203.

The DCCT Reseach Group. Effect of intensive diabetes management on macrovascular events and risk factors in the diabetes Control and Complications Trial. Am J Cardiol 1995; 75:894- 903.

The DCCT Reseach Group. The effect of intensive treatment of diabetes on the development and progression of long term complications. N Engl J Med 1993; 329:977-986.

The expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Report of the expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 1997, 20: 1183-1197.

The Sixth Report of the Joint National Committeee on Prevention, Detection, Evaluation and treatment of High Blood Pressure. Arch Intern Med 1997; 157:2413-2446.

Tuomi T, Groop LC, Zimmet PZ, Rowley MJ, Knowles W, Mackay IR. Antibodies to glutamic acid decarbixylase reveal latent autoimmune diabetes mellitus in adults with a non-insulin-dependent onset of disease. Diabetes 1993; 42:358-62.

UKPDS 33. An intensive blood glucose control policy with sulphonilureas or insulin reduces the risk of diabetic complications in patients with type 2 diabetes. Lancet 1998; 352:837-53.

Weetman AP. Hypothyroidism: screening and subclinical disease. B M J 1997; 314: 1175-1178.

White JR. The pharmacological reduction of blood glucose in patients with type 2 diabetes mellitus. Clin Diabetes 1998; 16:58-67.

Zimmet P, Turner R, McCarty D, Rowley M, Mackay I. Crucial Points at diagnosis. Type 2 diabetes or slow type 1 diabetes. Diabetes Care 1999; 22 (Suppl 2): B59-B64.